Digene DNA Pap Approval Anticipation Boosts Stock 45% In February

Investor expectations for imminent approval of Digene's HPV DNA Pap test as a primary screen for cervical cancer appeared to drive a 44.6% increase in the company's stock price to $16.59 in February